Adam M. Brufsky, MD, PhD, is Professor of Medicine at the University of Pittsburgh School of Medicine. He serves as Co-Director, Comprehensive Breast Cancer Center and Medical Director, Women’s Cancer Center at the Magee-Womens Hospital/UPCI, Pittsburgh, PA. He also serves as the Associate Division Chief for the Division of Hematology/Oncology within the University of Pittsburgh School of Medicine’s Department of Medicine. Additionally, Dr. Brufsky is the Associate Director for Translational Investigation for the UPMC Hillman Cancer Center. Dr. Brufsky received an in Chemistry (Cum Laude) from Dartmouth College in Hanover, New Hampshire. He earned his MD and his PhD in Developmental Biology at the University of Connecticut School of Medicine in Farmington, CT. He was an Intern and Resident in Internal Medicine at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He then completed a Fellowship in Medical Oncology and Bone Marrow Transplantation and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, where his appointments included Associate Physician and Instructor in Medicine at Dana Farber Cancer Institute and Harvard Medical School in Boston, MA.

Dr. Eitan Amir is a Medical Oncologist at Princess Margaret Cancer Centre in Toronto and an Associate Professor in the Department of Medicine at the University of Toronto. He also serves as the Cancer Care Ontario Systemic Therapy Lead for Toronto Central South and as the Vice-Chair of the Cancer Research Ethics Board at University Health Network. Dr. Amir’s clinical interests are the treatment of breast cancer and toxicities of anti-cancer drugs. His academic interests include clinical trial methodology, meta-analysis and outcomes research. Dr. Amir completed his medical degree, internal medicine and medical oncology training in the University of Manchester, UK. He then completed a PhD in Clinical Epidemiology at the University of Toronto. Dr. Amir has over 175 peer-reviewed publications as well as numerous published abstracts and book chapters.

Dr. Kurian’s research focuses on the identification of women with elevated breast and gynecologic cancer risk, and on the development and evaluation of novel techniques for early cancer detection and risk reduction. Dr. Kurian has published more than 100 peer-reviewed articles. As Director of the Stanford Women’s Clinical Cancer Genetics Program, her practice centers on women at high risk of breast and gynecologic cancers. Dr. Kurian develops evidence-based practice guidelines as a member of the National Comprehensive Cancer Network, and she recently led the American Society of Clinical Oncology’s Scientific Program Committee for Cancer Epidemiology and Prevention.

Dr. Smith is an Associate Professor of Radiation Oncology, with tenure, at The University of Texas MD Anderson Cancer Center and a board-certified radiation oncologist with expertise in breast cancer treatment and health services research. He is currently Chair of the American Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality Committee and has led ASTRO's efforts to develop evidence-based guidelines on accelerated partial breast radiation and whole breast irradiation. He has authored or co-authored over 100 articles, published in journals such as JAMA, Journal of the National Cancer Institute and the Journal of Clinical Oncology. Dr. Smith is the recipient of a Conquer Cancer Foundation Career Development Award, a Multi-Investigator Research Award from the Cancer Prevention and Research Institute of Texas, and is an Andrew Sabin Family Fellow at MD Anderson. Dr. Smith's research interests include prospective clinical trials in breast cancer radiation and health services research. Clinically, Dr. Smith specializes in breast cancer, and has a particular clinical interest in the care of elderly women and those with locally advanced disease.

Charles E. Geyer, Jr. is Professor of Medicine and the Harrigan, Haw, Luck Families Chair in Cancer Research at Virginia Commonwealth University Massey Cancer Center, an NCI-designated Cancer Center. He serves as Associate Director of Clinical Research for the Massey Cancer Center with oversight responsibility for all cancer-related clinical research activities within the Center. Dr. Geyer has devoted most of his academic career on the design and conduct of multi-institutional, phase III clinical trials in breast cancer with a particular focus on the development of HER2 targeted therapies. He has served in several leadership positions for multi-institution research initiatives. These include vice-chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Committee from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011. In 2008, he was appointed as a founding Co-chair for the NCI Cancer Treatment Evaluation Program Breast Cancer Steering Committee and received a Director’s Award at the completion of his tenure in 2011. Dr. Geyer has co-authored over 60 peer-reviewed manuscripts including results of several landmark phase 3 trials conducted by the NSABP. He has also been active in leadership roles on collaborative global trials in breast cancer, having chaired or co-chaired Scientific Steering Committees on 4 phase III trials. He earned his bachelor’s and doctoral degrees from Texas Tech University.

Dr. Li a biostatistician with broad interests in the research of chronic disease, including cancer, renal disease, cardiovascular disease, and diabetes. He has published more than 150 research papers, many of which have appeared in top statistical journals. For the past several years, Dr. Li has focused his effort in the measure development for the evaluation of facility performance in chronic disease management. This research has led to numerous NIH and CMS grants/contracts. He is now the PI or the statistical PI for several grants and contracts at UM’s Kidney Epidemiology and Cost Center (KECC). Dr. Li is actively involved in collaborative research in clinical trials and observational studies with researchers from various universities within the United States such as University of Michigan, Harvard University and Duke University. His statistical expertise includes big data analysis, hierarchical modeling, survival analysis, risk assessment and score development. Dr. Li is taking a prominent role in the statistical society and is currently serving as an AE for numerous major statistical journals, including JASA, Biometrics, and Scandinavia Journal of Statistics. In addition, Dr. Li holds positions on various NIH and NSF grant review panels.

Martha Goetsch MD MPH is a former ObGyn who trained at Oregon Health & Science University (1979) and has had a 35 year focus on vulvar pain within my generalist academic practice first at a community hospital for 20 years and then at OHSU for the last 17 years. She is presently retired from clinical practice and supervising an RCT on dyspareunia in postmenopausal women. Her expertise regarding survivors of breast cancer relates to their issues of dyspareunia, having published a trial of a nonhormonal therapy to prevent dyspareunia pain with a 95% success rate.

Dr. Burstein graduated from Harvard College before earning his MD at Harvard Medical School. He also received a PhD in cellular immunology and a master's degree in the history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital before his oncology fellowship at DFCI. In 1999, he joined the staff of DFCI and Brigham and Women's Hospital, where he is a clinician and clinical investigator in the Breast Oncology Center.